Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Other Non-Current Liabilities (2021 - 2025)

Oncology Institute's Other Non-Current Liabilities history spans 5 years, with the latest figure at $12.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 3170.39% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, up 3170.39%, while the annual FY2025 figure was $12.6 million, 3170.39% up from the prior year.
  • Other Non-Current Liabilities reached $12.6 million in Q4 2025 per TOI's latest filing, up from $3000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $12.6 million in Q3 2022 to a low of $3000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $3.5 million, with a median of $2.5 million recorded in 2022.
  • The largest YoY upside for Other Non-Current Liabilities was 3170.39% in 2025 against a maximum downside of 98.05% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $6.9 million in 2021, then plummeted by 42.61% to $4.0 million in 2022, then tumbled by 90.78% to $365000.0 in 2023, then increased by 5.48% to $385000.0 in 2024, then soared by 3170.39% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Other Non-Current Liabilities are $12.6 million (Q4 2025), $3000.0 (Q3 2025), and $10000.0 (Q2 2025).